

REMARKS

Upon entry of the foregoing amendment, claims 38 to 43, 47, 48, 51, 55 to 59, 62 and 63 are currently pending in this application. Claims 31 and 35 are canceled herein. Applicant reserves the right to pursue the subject matter of these claims in any future continuation or divisional applications. Previously withdrawn claims 47 and 48 are rejoined into the application, per the Examiner's comments on page 2 of the December 10, 2004 Office Action.

Applicants appreciate the Examiner's comment that claims 38 to 43, 47, 48, 51, 55 to 59, 62 and 63 are allowable.

Applicants respectfully request that the Examiner reconsider and withdraw the outstanding rejections and pass the application to allowance.

CONCLUSION

In view of the foregoing claim cancellations and amendments, Applicants believe all of the stated grounds of the rejections have been properly traversed and overcome. Therefore, Applicant respectfully requests that the outstanding rejections be withdrawn and claims 31, 35, 42, 47-48, 51, 55-59 and 62-63 be allowed. If the Examiner believes that personal communication will expedite prosecution of this application, the Examiner is invited to telephone the undersigned at the number provided.

Respectfully submitted,

Date: February 15, 2005

Keith D. Hutchinson
Keith D. Hutchinson
Attorney For Applicants
Registration No. 43,687

Agouron Pharmaceuticals, Inc./A Pfizer Company
Patent Department
10777 Science Center Drive
San Diego, California 92121
Phone: (858) 526-4608
Fax: (858) 678-8233